These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1929 related articles for article (PubMed ID: 28978710)

  • 61. Conserved stem fragment from H3 influenza hemagglutinin elicits cross-clade neutralizing antibodies through stalk-targeted blocking of conformational change during membrane fusion.
    Gong X; Yin H; Shi Y; Guan S; He X; Yang L; Yu Y; Kuai Z; Jiang C; Kong W; Wang S; Shan Y
    Immunol Lett; 2016 Apr; 172():11-20. PubMed ID: 26875772
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Broadened immunity and protective responses with emulsion-adjuvanted H5 COBRA-VLP vaccines.
    Allen JD; Owino SO; Carter DM; Crevar CJ; Reese VA; Fox CB; Coler RN; Reed SG; Baldwin SL; Ross TM
    Vaccine; 2017 Sep; 35(38):5209-5216. PubMed ID: 28789850
    [TBL] [Abstract][Full Text] [Related]  

  • 63. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 64. An Improved Inactivated Influenza Vaccine with Enhanced Cross Protection.
    Ni Y; Guo J; Turner D; Tizard I
    Front Immunol; 2018; 9():1815. PubMed ID: 30140267
    [TBL] [Abstract][Full Text] [Related]  

  • 65. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
    Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M
    Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Amino Acids in Hemagglutinin Antigenic Site B Determine Antigenic and Receptor Binding Differences between A(H3N2)v and Ancestral Seasonal H3N2 Influenza Viruses.
    Wang X; Ilyushina NA; Lugovtsev VY; Bovin NV; Couzens LK; Gao J; Donnelly RP; Eichelberger MC; Wan H
    J Virol; 2017 Jan; 91(2):. PubMed ID: 27807224
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Influenza H3 hemagglutinin vaccine with scrambled immunodominant epitopes elicits antibodies directed toward immunosubdominant head epitopes.
    Chiba S; Kong H; Neumann G; Kawaoka Y
    mBio; 2023 Aug; 14(4):e0062223. PubMed ID: 37466314
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Universal Dengue Vaccine Elicits Neutralizing Antibodies against Strains from All Four Dengue Virus Serotypes.
    Uno N; Ross TM
    J Virol; 2021 Jan; 95(4):. PubMed ID: 33208445
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Design of Nanoparticulate Group 2 Influenza Virus Hemagglutinin Stem Antigens That Activate Unmutated Ancestor B Cell Receptors of Broadly Neutralizing Antibody Lineages.
    Corbett KS; Moin SM; Yassine HM; Cagigi A; Kanekiyo M; Boyoglu-Barnum S; Myers SI; Tsybovsky Y; Wheatley AK; Schramm CA; Gillespie RA; Shi W; Wang L; Zhang Y; Andrews SF; Joyce MG; Crank MC; Douek DC; McDermott AB; Mascola JR; Graham BS; Boyington JC
    mBio; 2019 Feb; 10(1):. PubMed ID: 30808695
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection.
    DeDiego ML; Anderson CS; Yang H; Holden-Wiltse J; Fitzgerald T; Treanor JJ; Topham DJ
    Immunology; 2016 Jun; 148(2):160-73. PubMed ID: 26854888
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Next Generation of Computationally Optimized Broadly Reactive HA Vaccines Elicited Cross-Reactive Immune Responses and Provided Protection against H1N1 Virus Infection.
    Huang Y; França MS; Allen JD; Shi H; Ross TM
    Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358209
    [TBL] [Abstract][Full Text] [Related]  

  • 72. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination.
    Moody MA; Zhang R; Walter EB; Woods CW; Ginsburg GS; McClain MT; Denny TN; Chen X; Munshaw S; Marshall DJ; Whitesides JF; Drinker MS; Amos JD; Gurley TC; Eudailey JA; Foulger A; DeRosa KR; Parks R; Meyerhoff RR; Yu JS; Kozink DM; Barefoot BE; Ramsburg EA; Khurana S; Golding H; Vandergrift NA; Alam SM; Tomaras GD; Kepler TB; Kelsoe G; Liao HX; Haynes BF
    PLoS One; 2011; 6(10):e25797. PubMed ID: 22039424
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Next-Generation Influenza HA Immunogens and Adjuvants in Pursuit of a Broadly Protective Vaccine.
    Nagashima KA; Mousa JJ
    Viruses; 2021 Mar; 13(4):. PubMed ID: 33805245
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
    Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs.
    Kishida N; Fujisaki S; Yokoyama M; Sato H; Saito R; Ikematsu H; Xu H; Takashita E; Tashiro M; Takao S; Yano T; Suga T; Kawakami C; Yamamoto M; Kajiyama K; Saito H; Shimada S; Watanabe S; Aoki S; Taira K; Kon M; Lin JH; Odagiri T
    Clin Vaccine Immunol; 2012 Jun; 19(6):897-908. PubMed ID: 22492743
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Imprinting of Repeated Influenza A/H3 Exposures on Antibody Quantity and Antibody Quality: Implications for Seasonal Vaccine Strain Selection and Vaccine Performance.
    Kosikova M; Li L; Radvak P; Ye Z; Wan XF; Xie H
    Clin Infect Dis; 2018 Oct; 67(10):1523-1532. PubMed ID: 29672713
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins.
    Wang TT; Tan GS; Hai R; Pica N; Petersen E; Moran TM; Palese P
    PLoS Pathog; 2010 Feb; 6(2):e1000796. PubMed ID: 20195520
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Evaluation of three live attenuated H2 pandemic influenza vaccine candidates in mice and ferrets.
    Chen GL; Lamirande EW; Cheng X; Torres-Velez F; Orandle M; Jin H; Kemble G; Subbarao K
    J Virol; 2014 Mar; 88(5):2867-76. PubMed ID: 24371061
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines.
    Wang S; Taaffe J; Parker C; Solórzano A; Cao H; García-Sastre A; Lu S
    J Virol; 2006 Dec; 80(23):11628-37. PubMed ID: 16987975
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Next-Generation Computationally Designed Influenza Hemagglutinin Vaccines Protect against H5Nx Virus Infections.
    Nuñez IA; Huang Y; Ross TM
    Pathogens; 2021 Oct; 10(11):. PubMed ID: 34832509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 97.